BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23528871)

  • 1. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.
    Weber G; Gerdemann U; Caruana I; Savoldo B; Hensel NF; Rabin KR; Shpall EJ; Melenhorst JJ; Leen AM; Barrett AJ; Bollard CM
    Leukemia; 2013 Jul; 27(7):1538-47. PubMed ID: 23528871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The in vitro generation of multi-tumor antigen-specific cytotoxic T cell clones: Candidates for leukemia adoptive immunotherapy following allogeneic stem cell transplantation.
    Mohamed YS; Bashawri LA; Vatte C; Abu-Rish EY; Cyrus C; Khalaf WS; Browning MJ
    Mol Immunol; 2016 Sep; 77():79-88. PubMed ID: 27490939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
    Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
    Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.
    St John LS; Wan L; He H; Garber HR; Clise-Dwyer K; Alatrash G; Rezvani K; Shpall EJ; Bollard CM; Ma Q; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):995-1001. PubMed ID: 27378343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.
    Weber G; Caruana I; Rouce RH; Barrett AJ; Gerdemann U; Leen AM; Rabin KR; Bollard CM
    Clin Cancer Res; 2013 Sep; 19(18):5079-91. PubMed ID: 23838315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.
    Amrolia PJ; Reid SD; Gao L; Schultheis B; Dotti G; Brenner MK; Melo JV; Goldman JM; Stauss HJ
    Blood; 2003 Feb; 101(3):1007-14. PubMed ID: 12393606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wilms' tumor 1-specific cytotoxic T lymphocytes can be expanded from adult donors and cord blood.
    Krishnadas DK; Stamer MM; Dunham K; Bao L; Lucas KG
    Leuk Res; 2011 Nov; 35(11):1520-6. PubMed ID: 21774984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults.
    LaVoy EC; Bollard CM; Hanley PJ; Blaney JW; O'Connor DP; Bosch JA; Simpson RJ
    Exerc Immunol Rev; 2015; 21():144-53. PubMed ID: 25826370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.
    Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels WS; Jäger E; Bader P
    Leukemia; 2009 Sep; 23(9):1634-42. PubMed ID: 19357702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction.
    Montagna D; Daudt L; Locatelli F; Montini E; Turin I; Lisini D; Giorgiani G; Bernardo ME; Maccario R
    Cancer Res; 2006 Jul; 66(14):7310-6. PubMed ID: 16849581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.
    Tyler EM; Jungbluth AA; O'Reilly RJ; Koehne G
    Blood; 2013 Jan; 121(2):308-17. PubMed ID: 23160468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model.
    Ma Q; Wang C; Jones D; Quintanilla KE; Li D; Wang Y; Wieder ED; Clise-Dwyer K; Alatrash G; Mj Y; Munsell MF; Lu S; Qazilbash MH; Molldrem JJ
    Cytotherapy; 2010 Dec; 12(8):1056-62. PubMed ID: 20735170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.
    Matsushita M; Yamazaki R; Ikeda H; Mori T; Sumimoto H; Fujita T; Okamoto S; Ikeda Y; Kawakami Y
    Br J Haematol; 2006 Jan; 132(1):56-65. PubMed ID: 16371020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Ishikawa T; Fujii N; Imada M; Aoe M; Meguri Y; Inomata T; Nakashima H; Fujii K; Yoshida S; Nishimori H; Matsuoka KI; Kondo E; Maeda Y; Tanimoto M
    Cytotherapy; 2017 Apr; 19(4):514-520. PubMed ID: 28139337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
    Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
    Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
    Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.
    Ho WY; Nguyen HN; Wolfl M; Kuball J; Greenberg PD
    J Immunol Methods; 2006 Mar; 310(1-2):40-52. PubMed ID: 16469329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of melanoma-specific cytotoxic T lymphocytes for allogeneic immunotherapy.
    Nolte A; Scheffold C; Slotty J; Huenefeld C; Schultze JL; Grabbe S; Berdel WE; Kienast J
    J Immunother; 2003; 26(3):257-69. PubMed ID: 12806279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of BAX inhibitor-1 as a novel leukemia-associated antigen.
    Schmidt SM; König T; Bringmann A; Held S; von Schwarzenberg K; Heine A; Holderried TA; Stevanovic S; Grünebach F; Brossart P
    Leukemia; 2009 Oct; 23(10):1818-24. PubMed ID: 19609282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.